The numbers don’t lie, but they sure as hell don’t tell the whole story. Wildcat Capital Management, the New York outfit that once held 495,606 shares of UroGen Pharma Ltd. (URGN 1.05%), decided the party was over. Filed with the SEC on November 13: a clean break, a $6.79 million exit, and a whisper of dust where conviction once sat.
The stock had pulled a Houdini-up 113% in a year, laughing at the S&P’s meek 15% crawl. UroGen’s market cap swelled to $1.1 billion, a ghost of a thing built on $96.52 million in revenue and a net loss wider than the Grand Canyon. But Wall Street’s circus never rewards the clowns who stay on the tightrope too long.
Wildcat’s new poker hand reads like a noir deck: $123.89 million in ULCC, a desperation bet on RLX at $16.88 million, and pocket change in ALLO, TTAN, and GTLB. Their former stake-4% of assets-now looks like yesterday’s newspaper, ink smudged and headlines forgotten.
Jelmyto, UroGen’s crown jewel, still drips its pyelocalyceal solution into the void. The pipeline advances-UGN-102, UGN-301-with the slow inevitability of a leaky faucet. Their hydrogel tech sticks like gum on a cop’s shoe, promising better drug delivery for cancers that don’t care about promises. The whole operation runs on the biotech equivalent of whiskey and cigarettes: hope, a dash of science, and the quiet understanding that most trials end in tombstones.
Bonderman’s ghost hangs over this play. Wildcat wasn’t built for quick scores-it was a vault for billion-dollar patience. But even patient capital blinks when the lights glare too bright. Selling at the top isn’t a confession; it’s arithmetic with a bloodstained calculator. UroGen’s rally was a moonshot that’d make a gambler blush, but biotech winners rarely move straight. They stagger, zigzag, and leave the weak-kneed in the gutter.
The glossary terms spin like roulette wheels: AUM, TTM, proprietary pipelines. Liquidation isn’t defeat-it’s the house collecting its chips before the table burns down. Exposure’s a funny word when the market’s got knives in its pockets. And “asymmetric upside”? Sounds like a line from a eulogy for a stock that soared too close to the sun.
The silence in the trading room was as loud as a forgotten tomb. 🧠
| Metric | Value |
|---|---|
| Price (as of Friday) | $23.52 |
| Market Capitalization | $1.10 billion |
| Revenue (TTM) | $96.52 million |
| Net Income (TTM) | ($164.64 million) |
Read More
- 🚀 Doge’s Zero-Hour: Will It Go From Hero to Zero? 😱
- Sanctions Turn Russia’s Crypto Ban into a World-Class Gimmick! 🤑
- STX PREDICTION. STX cryptocurrency
- Billionaire’s Crypto Shuffle: What IS He Up To?! 🧐
- 2025’s Golden and Silver Tapestry: A Wily Investor’s Guide to ETFs
- 5 Energy Stocks for Discerning Investors: A Turgenevian Perspective
- 🤑 Bitcoin’s Bearish Ballet: A Comedy of Errors? 🕺
- XRP Outruns Bitcoin: Quantum Apocalypse or Just a Crypto Flex? 🚀
- Tether’s Sinister Plan Unveiled 🤫
- Most Overrated Sci-Fi Movies Everyone Seems To Like
2025-12-26 21:22